Current Status of Gene Expression Profiling to Assist Decision Making in Stage II Colon Cancer

Overview

Journal Oncologist

Publisher Oxford University Press

Specialty Oncology

Date 2014 May 30

PMID 24869929

Citations 9

Authors

Cheng E Chee

Neal J Meropol

Affiliations

Soon will be listed here.

Abstract

The decision regarding adjuvant therapy for patients with stage II colon cancer remains a challenge. In contrast to stage III colon cancer, for which compelling clinical data support the use of adjuvant chemotherapy, the clinical benefit of systemic therapy in unselected patients with stage II disease is modest at best. Risk stratification based on clinicopathologic features and DNA mismatch repair status is commonly used in adjuvant therapy decisions, but these factors do not have a desired level of precision in identifying patients at high risk. Recently, gene expression platforms have been developed to further define risk and to assist in therapeutic decision making for patients with stage II disease. This review describes those platforms that are furthest along in clinical development, in an effort to place their potential clinical application in context.

Citing Articles

Plasma Circulating mRNA Profile for the Non-Invasive Diagnosis of Colorectal Cancer Using NanoString Technologies.

Tsang H, Pei X, Wong Y, Wong S Int J Mol Sci. 2024; 25(5).

PMID: 38474258 PMC: 10932272. DOI: 10.3390/ijms25053012.

Artificial intelligence, molecular subtyping, biomarkers, and precision oncology.

Shen J Emerg Top Life Sci. 2021; 5(6):747-756.

PMID: 34881776 PMC: 8786277. DOI: 10.1042/ETLS20210212.

Prognostic and Predictive Molecular Biomarkers for Colorectal Cancer: Updates and Challenges.

Koncina E, Haan S, Rauh S, Letellier E Cancers (Basel). 2020; 12(2).

PMID: 32019056 PMC: 7072488. DOI: 10.3390/cancers12020319.

Making sense of adjuvant chemotherapy in colorectal cancer.

Chan G, Chee C J Gastrointest Oncol. 2020; 10(6):1183-1192.

PMID: 31949938 PMC: 6954995. DOI: 10.21037/jgo.2019.06.03.

MicroRNAs and their role for T stage determination and lymph node metastasis in early colon carcinoma.

Rammer M, Webersinke G, Haitchi-Petnehazy S, Maier E, Hackl H, Charoentong P Clin Exp Metastasis. 2017; 34(6-7):431-440.

PMID: 29134398 DOI: 10.1007/s10585-017-9863-9.

References

Sargent D, Goldberg R, JACOBSON S, Macdonald J, Labianca R, Haller D . A pooled analysis of adjuvant chemotherapy for resected colon cancer in elderly patients. N Engl J Med. 2001; 345(15):1091-7. DOI: 10.1056/NEJMoa010957. View

Roth A, Delorenzi M, Tejpar S, Yan P, Klingbiel D, Fiocca R . Integrated analysis of molecular and clinical prognostic factors in stage II/III colon cancer. J Natl Cancer Inst. 2012; 104(21):1635-46. DOI: 10.1093/jnci/djs427. View

Tournigand C, Andre T, Bonnetain F, Chibaudel B, Lledo G, Hickish T . Adjuvant therapy with fluorouracil and oxaliplatin in stage II and elderly patients (between ages 70 and 75 years) with colon cancer: subgroup analyses of the Multicenter International Study of Oxaliplatin, Fluorouracil, and Leucovorin in the.... J Clin Oncol. 2012; 30(27):3353-60. DOI: 10.1200/JCO.2012.42.5645. View

Meropol N . Ongoing challenge of stage II colon cancer. J Clin Oncol. 2011; 29(25):3346-8. DOI: 10.1200/JCO.2011.35.4571. View

Liefers G, Cleton-Jansen A, van de Velde C, Hermans J, van Krieken J, Cornelisse C . Micrometastases and survival in stage II colorectal cancer. N Engl J Med. 1998; 339(4):223-8. DOI: 10.1056/NEJM199807233390403. View

Nosho K, Yamamoto H, Taniguchi H, Adachi Y, Yoshida Y, Arimura Y . Interplay of insulin-like growth factor-II, insulin-like growth factor-I, insulin-like growth factor-I receptor, COX-2, and matrix metalloproteinase-7, play key roles in the early stage of colorectal carcinogenesis. Clin Cancer Res. 2004; 10(23):7950-7. DOI: 10.1158/1078-0432.CCR-04-0875. View

Glas A, Floore A, Delahaye L, Witteveen A, Pover R, Bakx N . Converting a breast cancer microarray signature into a high-throughput diagnostic test. BMC Genomics. 2006; 7:278. PMC: 1636049. DOI: 10.1186/1471-2164-7-278. View

Waldman S, Hyslop T, Schulz S, Barkun A, Nielsen K, Haaf J . Association of GUCY2C expression in lymph nodes with time to recurrence and disease-free survival in pN0 colorectal cancer. JAMA. 2009; 301(7):745-52. PMC: 2756012. DOI: 10.1001/jama.2009.141. View

Schulz S, Hyslop T, Haaf J, Bonaccorso C, Nielsen K, Witek M . A validated quantitative assay to detect occult micrometastases by reverse transcriptase-polymerase chain reaction of guanylyl cyclase C in patients with colorectal cancer. Clin Cancer Res. 2006; 12(15):4545-52. DOI: 10.1158/1078-0432.CCR-06-0865. View

10.

Paik S, Shak S, Tang G, Kim C, Baker J, Cronin M . A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med. 2004; 351(27):2817-26. DOI: 10.1056/NEJMoa041588. View

11.

Waldman S, Cagir B, Rakinic J, Fry R, Goldstein S, Isenberg G . Use of guanylyl cyclase C for detecting micrometastases in lymph nodes of patients with colon cancer. Dis Colon Rectum. 1998; 41(3):310-5. DOI: 10.1007/BF02237484. View

12.

Nicastri D, Doucette J, Godfrey T, Hughes S . Is occult lymph node disease in colorectal cancer patients clinically significant? A review of the relevant literature. J Mol Diagn. 2007; 9(5):563-71. PMC: 2049052. DOI: 10.2353/jmoldx.2007.070032. View

13.

Sargent D, Marsoni S, Monges G, Thibodeau S, Labianca R, Hamilton S . Defective mismatch repair as a predictive marker for lack of efficacy of fluorouracil-based adjuvant therapy in colon cancer. J Clin Oncol. 2010; 28(20):3219-26. PMC: 2903323. DOI: 10.1200/JCO.2009.27.1825. View

14.

Samowitz W, Sweeney C, Herrick J, Albertsen H, Levin T, Murtaugh M . Poor survival associated with the BRAF V600E mutation in microsatellite-stable colon cancers. Cancer Res. 2005; 65(14):6063-9. DOI: 10.1158/0008-5472.CAN-05-0404. View

15.

OConnell M, Lavery I, Yothers G, Paik S, Clark-Langone K, Lopatin M . Relationship between tumor gene expression and recurrence in four independent studies of patients with stage II/III colon cancer treated with surgery alone or surgery plus adjuvant fluorouracil plus leucovorin. J Clin Oncol. 2010; 28(25):3937-44. PMC: 2940392. DOI: 10.1200/JCO.2010.28.9538. View

16.

Salazar R, Roepman P, Capella G, Moreno V, Simon I, Dreezen C . Gene expression signature to improve prognosis prediction of stage II and III colorectal cancer. J Clin Oncol. 2010; 29(1):17-24. DOI: 10.1200/JCO.2010.30.1077. View

17.

Twelves C, Wong A, Nowacki M, Abt M, Burris 3rd H, Carrato A . Capecitabine as adjuvant treatment for stage III colon cancer. N Engl J Med. 2005; 352(26):2696-704. DOI: 10.1056/NEJMoa043116. View

18.

Greene F, Stewart A, Norton H . A new TNM staging strategy for node-positive (stage III) colon cancer: an analysis of 50,042 patients. Ann Surg. 2002; 236(4):416-21; discussion 421. PMC: 1422595. DOI: 10.1097/00000658-200210000-00003. View

19.

Dahlin A, Palmqvist R, Henriksson M, Jacobsson M, Eklof V, Rutegard J . The role of the CpG island methylator phenotype in colorectal cancer prognosis depends on microsatellite instability screening status. Clin Cancer Res. 2010; 16(6):1845-55. DOI: 10.1158/1078-0432.CCR-09-2594. View

20.

Gray R, Quirke P, Handley K, Lopatin M, Magill L, Baehner F . Validation study of a quantitative multigene reverse transcriptase-polymerase chain reaction assay for assessment of recurrence risk in patients with stage II colon cancer. J Clin Oncol. 2011; 29(35):4611-9. DOI: 10.1200/JCO.2010.32.8732. View